Nihon Kohden Corp
TSE:6849
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Nihon Kohden Corp
Net Income (Common)
Nihon Kohden Corp
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Nihon Kohden Corp
TSE:6849
|
Net Income (Common)
¥12.4B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
3%
|
|
|
Terumo Corp
TSE:4543
|
Net Income (Common)
¥127.9B
|
CAGR 3-Years
14%
|
CAGR 5-Years
11%
|
CAGR 10-Years
10%
|
|
|
Olympus Corp
TSE:7733
|
Net Income (Common)
¥84.8B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
44%
|
|
|
Sysmex Corp
TSE:6869
|
Net Income (Common)
¥44.7B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
7%
|
CAGR 10-Years
2%
|
|
|
JEOL Ltd
TSE:6951
|
Net Income (Common)
¥16.2B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
30%
|
CAGR 10-Years
11%
|
|
|
Fukuda Denshi Co Ltd
TSE:6960
|
Net Income (Common)
¥18B
|
CAGR 3-Years
3%
|
CAGR 5-Years
9%
|
CAGR 10-Years
9%
|
|
Nihon Kohden Corp
Glance View
Nihon Kohden Corp., founded in 1951, has evolved into a pioneering force in the medical technology landscape, blending innovation with a storied heritage. This Tokyo-based firm established its foothold by developing advanced medical electronic devices, initially focusing on EEG (electroencephalography) machines. As medical science rapidly advanced, Nihon Kohden expanded its portfolio to include a range of diagnostic and monitoring equipment. Today, the company's product line encompasses patient monitors, defibrillators, electrocardiographs, and clinical information systems, serving various healthcare domains. This focus on critical care and diagnostics creates consistent demand across global hospitals and clinics, reinforcing its reputation as a dependable partner in medical excellence. Financially, Nihon Kohden's business model thrives on a dual revenue structure: product sales and after-sales service. By manufacturing and distributing complex equipment directly and through a network of distributors, the company captures a significant share of initial capital expenditure in healthcare institutions. Furthermore, it enhances this income by offering ongoing equipment maintenance, training, and customer support, forming long-term relationships with healthcare providers. These services ensure not only a steady revenue stream beyond the initial sale but also brand loyalty and trust in an industry where precision and reliability are paramount. As it continues to innovate, Nihon Kohden's commitment to addressing the evolving needs of healthcare practitioners fortifies its market position and operational success.
See Also
What is Nihon Kohden Corp's Net Income (Common)?
Net Income (Common)
12.4B
JPY
Based on the financial report for Dec 31, 2025, Nihon Kohden Corp's Net Income (Common) amounts to 12.4B JPY.
What is Nihon Kohden Corp's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
3%
Over the last year, the Net Income (Common) growth was -28%. The average annual Net Income (Common) growth rates for Nihon Kohden Corp have been -7% over the past three years , -2% over the past five years , and 3% over the past ten years .